Shared on30 Aug 25Fair value Decreased 2.22%
Despite upgraded revenue growth forecasts and a sharply lower future P/E multiple, analysts have reduced their fair value estimate for Clinuvel Pharmaceuticals, lowering the consensus price target from A$24.42 to A$22.45. Valuation Changes Summary of Valuation Changes for Clinuvel Pharmaceuticals The Consensus Analyst Price Target has fallen from A$24.42 to A$22.45.
Shared on23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 12%
AnalystConsensusTarget has decreased revenue growth from 25.2% to 9.5%, decreased profit margin from 43.2% to 38.0% and increased future PE multiple from 21.3x to 32.0x.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on12 Mar 25Fair value Decreased 8.05%
AnalystConsensusTarget has increased revenue growth from 18.6% to 25.2% and decreased future PE multiple from 25.9x to 21.2x.